Bernhard Widmann1, Rene Warschkow2,3, Bruno M Schmied2, Lukas Marti2, Thomas Steffen2. 1. Department of General, Visceral, Endocrine and Transplantation Surgery, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland. bernhard.widmann@kssg.ch. 2. Department of General, Visceral, Endocrine and Transplantation Surgery, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland. 3. Institute of Medical Biometry and Informatics, University of Heidelberg, 69120, Heidelberg, Germany.
Abstract
BACKGROUND: Whereas the poor prognosis of signet ring cell adenocarcinomas of the appendix is well known, the significance of mucinous histology remains unclear. The aim of this population-based study was to evaluate if mucinous histology is an independent prognostic factor in appendiceal adenocarcinomas. METHODS: Patients with stage I-III adenocarcinoma of the appendix who underwent surgery between 2004 and 2012 were identified in the Surveillance, Epidemiology, and End Results database. Overall survival (OS) and cancer-specific survival (CSS) were assessed using risk-adjusted Cox proportional hazards regression models and propensity score methods. RESULTS: Overall, 980 patients with appendix cancer were included, of which 449 (45.8 %) had a mucinous histology. In an unadjusted analysis, the 5-year OS and CSS in patients with a mucinous adenocarcinoma (MC) was 76.8 % (95 % confidence interval (95 %CI): 72.1-81.7 %) and 81.0 % (95 %CI: 76.6-85.6 %), respectively, compared with 70.0 % (95 %CI: 65.1-75.3 %) and 76.2 % (95 %CI: 71.5-81.2 %) in patients with non-mucinous adenocarcinoma (NMC) (P = 0.082 and P = 0.368). In multivariable analysis, no impact on survival was observed for OS (HR = 1.22, 95 %CI: 0.89-1.68, P = 0.208) and CSS (HR = 1.21, 95 %CI: 0.84-1.74, P = 0.296). After propensity score matching, nearly identical survival rates were observed (OS: HR = 1.03, 95 %CI: 0.71-1.49, P = 0.881 and CSS: HR = 1.05, 95 %CI: 0.70-1.59, P = 0.803). CONCLUSIONS: The present population-based, propensity score matched analysis shows that mucinous histology does not affect survival in stage I-III appendiceal adenocarcinoma patients. Therefore, the same treatment strategies can be applied for patients with NMC and MC of the appendix.
BACKGROUND: Whereas the poor prognosis of signet ring cell adenocarcinomas of the appendix is well known, the significance of mucinous histology remains unclear. The aim of this population-based study was to evaluate if mucinous histology is an independent prognostic factor in appendiceal adenocarcinomas. METHODS:Patients with stage I-III adenocarcinoma of the appendix who underwent surgery between 2004 and 2012 were identified in the Surveillance, Epidemiology, and End Results database. Overall survival (OS) and cancer-specific survival (CSS) were assessed using risk-adjusted Cox proportional hazards regression models and propensity score methods. RESULTS: Overall, 980 patients with appendix cancer were included, of which 449 (45.8 %) had a mucinous histology. In an unadjusted analysis, the 5-year OS and CSS in patients with a mucinous adenocarcinoma (MC) was 76.8 % (95 % confidence interval (95 %CI): 72.1-81.7 %) and 81.0 % (95 %CI: 76.6-85.6 %), respectively, compared with 70.0 % (95 %CI: 65.1-75.3 %) and 76.2 % (95 %CI: 71.5-81.2 %) in patients with non-mucinous adenocarcinoma (NMC) (P = 0.082 and P = 0.368). In multivariable analysis, no impact on survival was observed for OS (HR = 1.22, 95 %CI: 0.89-1.68, P = 0.208) and CSS (HR = 1.21, 95 %CI: 0.84-1.74, P = 0.296). After propensity score matching, nearly identical survival rates were observed (OS: HR = 1.03, 95 %CI: 0.71-1.49, P = 0.881 and CSS: HR = 1.05, 95 %CI: 0.70-1.59, P = 0.803). CONCLUSIONS: The present population-based, propensity score matched analysis shows that mucinous histology does not affect survival in stage I-III appendiceal adenocarcinomapatients. Therefore, the same treatment strategies can be applied for patients with NMC and MC of the appendix.
Entities:
Keywords:
Appendix cancer; Mucinous adenocarcinoma; Propensity score; SEER; Surveillance, Epidemiology, and End Results Program
Authors: V Catalano; F Loupakis; F Graziano; R Bisonni; U Torresi; B Vincenzi; D Mari; P Giordani; P Alessandroni; L Salvatore; L Fornaro; D Santini; A M Baldelli; D Rossi; L Giustini; R R Silva; A Falcone; S D'Emidio; M Rocchi; S Luzi Fedeli Journal: Ann Oncol Date: 2011-04-29 Impact factor: 32.976
Authors: Phyllis A Wingo; Patricia M Jamison; Robert A Hiatt; Hannah K Weir; Paul M Gargiullo; Mary Hutton; Nancy C Lee; H Irene Hall Journal: Cancer Causes Control Date: 2003-03 Impact factor: 2.506
Authors: Elliot A Asare; Carolyn C Compton; Nader N Hanna; Lauren A Kosinski; Mary Kay Washington; Sanjay Kakar; Martin R Weiser; Michael J Overman Journal: Cancer Date: 2015-10-27 Impact factor: 6.860